Literature DB >> 1666631

Phase II trial of intravenous 6-thioguanine for unresectable or metastatic non-small cell bronchogenic carcinoma.

F V Fossella1, R J Winn, P Y Holoye, M N Raber, L Holden, R Belt, H Allen, B Hallinan, K Harper.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1666631     DOI: 10.1007/bf00183586

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  5 in total

1.  The metabolism of 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in man.

Authors:  G B ELION; S W CALLAHAN; G H HITCHINGS; R W RUNDLES
Journal:  Cancer Chemother Rep       Date:  1960-07

2.  Pharmacology of 6-thioguanine in man.

Authors:  G A LePage; J P Whitecar
Journal:  Cancer Res       Date:  1971-11       Impact factor: 12.701

3.  Clinical pharmacology of oral thioguanine in acute myelogenous leukemia.

Authors:  L W Brox; L Birkett; A Belch
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine.

Authors:  C A Presant; A E Denes; L Klein; S Garrett; G E Metter
Journal:  Cancer Treat Rep       Date:  1980 Oct-Nov

5.  Phase I trial of parenteral 6-thioguanine given on 5 consecutive days.

Authors:  J S Kovach; J Rubin; E T Creagan; A J Schutt; L K Kvols; P A Svingen; T C Hu
Journal:  Cancer Res       Date:  1986-11       Impact factor: 12.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.